<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01665573</url>
  </required_header>
  <id_info>
    <org_study_id>120303009906</org_study_id>
    <nct_id>NCT01665573</nct_id>
  </id_info>
  <brief_title>Cannabinoid Augmentation of Fear Response in Humans</brief_title>
  <official_title>Cannabinoid Augmentation of Fear Response in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double blind, randomized, controlled, proof-of-concept study is to test&#xD;
      the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning. On&#xD;
      three days over not more than two weeks, subjects will be trained to associate cues with two&#xD;
      different stimuli, then this association will be extinguished. Cannabinoid receptor&#xD;
      stimulation will be accomplished indirectly by harnessing the brain's capacity to&#xD;
      endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents&#xD;
      degradation of anandamide. Subjects will receive placebo or the FAAH-inhibitor PF-04457845.&#xD;
      Some details of this study have not been disclosed to preserve the study design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Galvanic skin response</measure>
    <time_frame>Test days #1, #2, and #3, on average a week</time_frame>
    <description>Measure of sympathetic autonomic activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortisol levels measured in blood</measure>
    <time_frame>Test days #1, #2, and #3, on average a week</time_frame>
    <description>Salivary b-amylase and serum cortisol levels will be assessed as neurochemical measures of stress response.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fear Conditioning</condition>
  <arm_group>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acquisition of conditioning Administration of drug Extinction of conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04457845</intervention_name>
    <description>Acquisition of conditioning Administration of drug Extinction of conditioning</description>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acquisition of conditioning Administration of placebo Extinction of conditioning</description>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18 and 65&#xD;
&#xD;
          -  Male and female&#xD;
&#xD;
          -  No major medical problems&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hearing problems&#xD;
&#xD;
          -  Psychiatric or mental problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohini Ranganathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>August 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2012</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mohini Ranganathan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Fear Conditioning</keyword>
  <keyword>Cannabinoids</keyword>
  <keyword>Fear Response</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

